Back to search results

A Study of Eloralintide (LY3841136) in People with Kidney Impairment

This study is looking at how the body handles a drug called Eloralintide (LY3841136) when it's given to people with kidney problems and to healthy people. Researchers want to understand how much of the drug gets into the bloodstream and how quickly the body gets rid of it. Eloralintide (LY3841136) will be given as an injection under the skin. You might be able to join if you are between 18 and 85 years old, weigh at least 55 kilograms (about 121 pounds), and have a body mass index (BMI) between 19 and 40. The study is planning to include 28 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 28 participants.
What's involved
The study will last about 14 weeks for each participant, not including the initial screening period.
Compensation
Not stated in the trial record.
Follow-up
The drug levels will be measured from before the first dose up to Day 71.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07426380

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Active, Not Recruiting
PHASE1Ages 18–85InterventionalBasic science
Eli Lilly and Company
~28 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:LY3841136

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
Measured over Predose on Day 1 up to Day 71
+1 more outcome measured

Conditions

Kidney Disease
Renal Insufficiency Chronic
Kidney Failure, Chronic
Renal Impairment
Renal Insufficiency
End Stage Kidney Disease

Explore related trials

Chronic Kidney DiseaseChronic Kidney Disease, Stage 5Nephropathy

Where it's being run

2 sites across 1 states
Florida2

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a body weight of 55 kilograms (kg) or more and a body mass index (BMI) within the range of 19.0 to 40.0 kilograms per square meter (kg/m²), inclusive
Have no significant history of spontaneous or ethanol-induced hypoglycemia
Are healthy as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) of at least 90 milliliters per minute (mL/min)
Have glycated hemoglobin (HbA1c) less than or equal to 6.5% at screening
Have stable severe renal impairment, assessed by eGFR less than 30 mL/min at screening or with end-stage renal disease (ESRD) who have been on a stable hemodialysis (HD) schedule for at least 3 months prior to planned dosing
Have acceptable blood pressure and pulse rate
If participants have Type 2 Diabetes Mellitus (T2DM), they must have a HbA1c equal to or less than 10.0% at screening

Exclusion

Have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, any evidence for hepatic impairments
Have a current, functioning organ transplant. Nonfunctional renal allografts may be considered
Have significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational product; or interfering with the interpretation of data
Are receiving continuous HD or peritoneal dialysis.
Have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before eloralintide administration

What this trial measures

  • Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136Predose on Day 1 up to Day 71
  • PK: Maximum Observed Drug Concentration (Cmax) of LY3841136Predose on Day 1 up to Day 71